Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
PaperCitations, authors & open-access status
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 458 citations, 2019 year and bronze oa status.
458
Citations
2019
Year
bronze
OA Status